Yet another MS Drug Target in Development
Submitted by art on Wed, 2004-03-10 07:13.
The Seattle Times reports:
'ZymoGenetics has pinned its loftier ambitions — to become "an unacquired Immunex," as Carter says — on another protein in human testing, TACI-Ig, to treat the root causes for lupus, rheumatoid arthritis and possibly multiple sclerosis and cancer. Another candidate, IL-21, is to enter human tests this year. Those drugs will take years to show evidence of effectiveness in people and to drum up investor enthusiasm.'